![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
rhEGF (recombinant human epidermal growth factor) is a 53 amino acid polypeptide isolated for the first time from mice submaxillary glands. It is being evaluated for the treatment of complex and complicated refractory neuropathic, ischemic, and neuroischemic diabetic foot ulcers.
Lead Product(s): Recombinant Human Epidermal Growth Factor
Therapeutic Area: Podiatry Product Name: rhEGF
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024